STOCK TITAN

Aldeyra Therapeutics Inc - ALDX STOCK NEWS

Welcome to our dedicated news page for Aldeyra Therapeutics (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aldeyra Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aldeyra Therapeutics's position in the market.

Rhea-AI Summary
Aldeyra Therapeutics announces positive results from Phase 2 clinical trial of ADX-2191 for retinitis pigmentosa
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
-
-
Rhea-AI Summary
Aldeyra Therapeutics to announce top-line results from Phase 2 clinical trial of ADX-629 in patients with chronic cough.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.26%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.44%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
Aldeyra Therapeutics Inc

Nasdaq:ALDX

ALDX Rankings

ALDX Stock Data

227.93M
42.66M
2.01%
62.36%
3.48%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Lexington

About ALDX

dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise